Contrasting Globus Medical (NYSE:GMED) & IceCure Medical (NASDAQ:ICCM)

Globus Medical (NYSE:GMED) and IceCure Medical (NASDAQ:ICCM) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Globus Medical and IceCure Medical, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Globus Medical	0	3	7	0	2.70
IceCure Medical	0	0	2	0	3.00

Globus Medical currently has a consensus target price of $77.78, indicating a potential upside of 5.62%. IceCure Medical has a consensus target price of $2.70, indicating a potential upside of 390.91%. Given IceCure Medical’s stronger consensus rating and higher probable upside, analysts clearly believe IceCure Medical is more favorable than Globus Medical.

Institutional & Insider Ownership

95.2% of Globus Medical shares are owned by institutional investors. Comparatively, 0.6% of IceCure Medical shares are owned by institutional investors. 18.5% of Globus Medical shares are owned by company insiders. Comparatively, 2.4% of IceCure Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Globus Medical and IceCure Medical”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Globus Medical	$2.24 billion	4.46	$122.87 million	$0.64	115.06
IceCure Medical	$3.34 million	7.52	-$14.65 million	($0.33)	-1.67

Globus Medical has higher revenue and earnings than IceCure Medical. IceCure Medical is trading at a lower price-to-earnings ratio than Globus Medical, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Globus Medical has a beta of 1.17, meaning that its share price is 17% more volatile than the S&P 500. Comparatively, IceCure Medical has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500.

Profitability

This table compares Globus Medical and IceCure Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Globus Medical	1.82%	8.70%	6.87%
IceCure Medical	-410.22%	-111.27%	-81.41%

Summary

Globus Medical beats IceCure Medical on 11 of the 14 factors compared between the two stocks.

About Globus Medical

Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. It also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, the company distributes human cell, tissue, and cellular and tissue-based products. It sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.